News Center
2 months agoHealth
Treating Cardiovascular Health with Anti-Obesity Medications and Addressing Health Equity - News Center
GLP-1 receptor agonist medications like semaglutide can reduce the risk of cardiovascular disease in patients with obesity but no diabetes.
Weight-independent effects of semaglutide include reducing inflammation and improving vasculature and kidney health, leading to decreased development of cardiovascular events. [ more ]